Clinical Trials on Severe Hemophilia A in China

Total 816 results

Jiangsu Gensciences lnc.

Completed

A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Severe Hemophilia A

China
Jiangsu Gensciences lnc.

Completed

A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Severe Hemophilia A

China
Jiangsu Gensciences lnc.

Not yet recruiting

Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A

Severe Hemophilia A

China
Pfizer

Completed

Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia

Severe Hemophilia

China
Novo Nordisk A/S

Recruiting

A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors

Haemophilia A With Inhibitors | Haemophilia A

United States, Korea, Republic of, France, Spain, Romania, Canada, Taiwan, China, Lithuania, Netherlands, India, South Africa, Russian Federation, Austria, Belgium, Czechia, Denmark, Ireland, Italy, Japan, Latvia, Malaysia, Mexico, Po... and more
Novo Nordisk A/S

Recruiting

A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER 4) (FRONTIER4)

Haemophilia A With Inhibitors | Haemophilia A

Taiwan, Canada, Spain, Netherlands, Korea, Republic of, India, United States, United Kingdom, China, Portugal, Lithuania, Turkey, South Africa, Ireland, Italy, France, Japan, Belgium, Malaysia, Poland, Austria, Bulgaria, Denmark, Germany and more
Jiangsu Gensciences lnc.

Recruiting

Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein

Severe Hemophilia A

China
Beijing Children's Hospital

Unknown

A Clinical Phenotype Based Individualized Prophylaxis in Chinese Hemophilia A Children (CHIPS)

Haemophilia

China
Novo Nordisk A/S

Completed

Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10) (Pathfinder10)

Haemophilia A

China
Novo Nordisk A/S

Enrolling by invitation

Post-marketing Surveillance (Use Result Surveillance) With Refixia®

Haemophilia B

Japan, Denmark
Institute of Hematology & Blood Diseases Hospital

Recruiting

An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A (AHA2023)

Acquired Hemophilia

China
Peking Union Medical College Hospital

Unknown

Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A

Acquired Hemophilia A

China
Zhang Lei, MD
Henan Cancer Hospital; Qilu Hospital of Shandong University; Tianjin First Central... and other collaborators

Completed

Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab

Acquired Hemophilia A

China
Suzhou Alphamab Co., Ltd.

Recruiting

Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia.

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

China
Novo Nordisk A/S

Recruiting

A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors

Haemophilia A With or Without Inhibitors

India, China, Korea, Republic of, Canada, Spain, Netherlands, South Africa, United States, Israel, Poland, United Kingdom, Italy, Japan, Lithuania, Portugal, Switzerland, Taiwan
Institute of Hematology & Blood Diseases Hospital...
Sinocelltech Ltd.

Recruiting

ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor

Hemophilia A With Inhibitor

China
Beijing Children's Hospital

Unknown

Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China (HA-LD-ITI)

Hemophilia A With Inhibitor

China
Novo Nordisk A/S

Active, not recruiting

A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia B (Paradigm9)

Haemophilia B

China
Jiangsu Gensciences lnc.

Recruiting

SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment

Hemophilia | Hemophilia A With Inhibitor | Male | Hemophilia B With Inhibitor

China
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B

Severe Hemophilia B

Sweden, United States, France, Italy, Russian Federation, United Kingdom, Germany, China, Poland, Japan, Australia, Brazil, Canada, India, South Africa, Hong Kong, Belgium
Novo Nordisk A/S

Completed

Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (guardian TM 7)

Congenital Bleeding Disorder | Haemophilia A

China
Bioverativ Therapeutics Inc.

Completed

Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B (B-YOND)

Severe Hemophilia B

United States, Italy, Belgium, Australia, Brazil, Hong Kong, India, Ireland, Japan, South Africa, United Kingdom, Netherlands, Sweden, Canada, Poland, China, France, Germany
Jiangsu Gensciences lnc.

Completed

A Phase I of SS109 in Hemophilia A or and B With Inhibitors

Factor VII Deficiency | Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

China
Takeda

Completed

Study of TAK-672 in Participants With Acquired Hemophilia A

Acquired Hemophilia A

Japan
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A (guardian™4)

Congenital Bleeding Disorder | Haemophilia A

United States, Denmark, Austria, Spain, Japan, Brazil, Algeria, Lithuania, Portugal, Russian Federation, Serbia, Turkey, Greece, Hong Kong, Puerto Rico, Hungary, China, Poland
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients

Hemophilia B

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.

Hemophilia B

China
Shanghai Vitalgen BioPharma Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety and Efficacy of VGB-R04 in Adult Hemophilia B Patients

Hemophilia B

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Safety and Tolerability of VGB-R04 in Patients With Haemophilia B

Hemophilia B

China
Pfizer

Completed

An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects With Hemophilia B

Hemophilia B

China
Institute of Hematology & Blood Diseases Hospital
East China University of Science and Technology

Active, not recruiting

Gene Therapy for Chinese Hemophilia B

Hemophilia B

China
Bayer

Completed

A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150

Hemophilia A, Hemophilia B

Italy, China, New Zealand, Russian Federation, Taiwan, Singapore, Bulgaria, United States, Denmark, Germany, Hungary, South Africa, United Kingdom, Romania, Colombia, Mexico, Turkey, France, India, Japan, Australia, Netherlands, Poland and more
Xue-chun Lu

Recruiting

Combination Regimen With Sodium Valproate for Severe Hemophilia: a Single-arm, Phase 1, Pilot Trial.

Hemophilia

China
Sinocelltech Ltd.

Recruiting

Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.

Hemophilia A

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Completed

A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

Hemophilia

China
Pfizer

Completed

Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia A

Hemophilia A

China
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Safety and Efficacy Study of NGGT003 in Hemophilia A Patients

Hemophilia A

China
Suzhou Alphamab Co., Ltd.

Recruiting

KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia

Hemophilia

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Unknown

A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

Hemophilia

China
Sinocelltech Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Parexel; Q2...

Completed

Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A

Hemophilia A

China
Shanghai Belief-Delivery BioMed Co., Ltd
Shanghai MYGT Biopharmaceutical LLC

Recruiting

Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs

Hemophilia A

China
Beijing Children's Hospital

Unknown

Pharmacokinetic (PK)Research on Chinese Children of Hemophilia (PK)

Pharmacokinetics

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

A Study of FVIII Gene Therapy for Hemophilia A

Hemophilia A

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

The Efficacy and Safety of ZS802 in Chinese Hemophilia A Patients.

Hemophilia A

China
Hoffmann-La Roche

Completed

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers

Hemophilia A | Healthy Volunteers

China
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating On-Demand Treatment With BeneFIX In Chinese Subjects

Hemophilia B

China
Sinocelltech Ltd.

Unknown

Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A

Hemophilia A

China
Bayer

Completed

Retrospective Study in Chinese Pediatric Hemophilia A Patients With rFⅧ Contained Regular Prophylaxis (ReCARE)

Hemophilia A

China
Shenzhen Geno-Immune Medical Institute

Unknown

Lentiviral FVIII Gene Therapy

Hemophilia A

China

Clinical Trials on Severe Hemophilia A in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations